NUVECTIS PHARMA INC's ticker is and the CUSIP is 67080T108. A total of 1 filers reported holding NUVECTIS PHARMA INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $93,865 | +982.4% | 7,282 | +1241.1% | 0.00% | – |
| Q2 2023 | $8,672 | +288966.7% | 543 | +117.2% | 0.00% | – |
| Q1 2023 | $3 | -70.0% | 250 | -81.6% | 0.00% | – |
| Q4 2022 | $10 | -100.0% | 1,359 | -66.5% | 0.00% | – |
| Q3 2022 | $29,000 | +107.1% | 4,052 | +216.8% | 0.00% | – |
| Q2 2022 | $14,000 | +7.7% | 1,279 | -26.9% | 0.00% | – |
| Q1 2022 | $13,000 | – | 1,750 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BALDWIN BROTHERS LLC/MA | 116,380 | $1,500,138 | 0.13% |
| FORBES J M & CO LLP | 34,000 | $438,260 | 0.06% |
| Moran Wealth Management, LLC | 16,697 | $215,224 | 0.01% |
| Dorsey Wright & Associates | 1,396 | $17,994 | 0.01% |
| Tower Research Capital LLC (TRC) | 7,282 | $93,865 | 0.00% |
| MARSHALL WACE, LLP | 36,085 | $465,136 | 0.00% |
| Renaissance Technologies | 25,400 | $327 | 0.00% |
| UBS Group AG | 3,776 | $48,672 | 0.00% |
| RHUMBLINE ADVISERS | 7,273 | $93,742 | 0.00% |
| HOLLENCREST CAPITAL MANAGEMENT | 280 | $3,609 | 0.00% |